Analyst Activity – Cowen and Company Reiterates Outperform on Omeros (NASDAQ:OMER)

16

Analyst Ratings For Omeros (NASDAQ:OMER)

Today, Cowen and Company reiterated its Outperform rating on Omeros (NASDAQ:OMER).

There are 6 buy ratings on the stock.

The current consensus rating on Omeros (NASDAQ:OMER) is Buy (Score: 3.00) with a consensus target price of $33.38 per share, a potential 216.66% upside.

Some recent analyst ratings include

  • 3/20/2017-Cowen and Company Reiterated Rating of Outperform.
  • 3/17/2017-Cantor Fitzgerald Reiterated Rating of Overweight.
  • 3/17/2017-Maxim Group Reiterated Rating of Buy .
  • 3/17/2017-Needham & Company LLC Reiterated Rating of Buy .
  • 3/2/2017-FBR & Co Reiterated Rating of Buy.
  • 2/21/2017-Wedbush Reiterated Rating of Outperform.
  • 11/17/2016-WBB Securities Reiterated Rating of Buy.

Dividend information for Omeros (NASDAQ:OMER)

.
Recent Insider Trading Activity For Omeros (NASDAQ:OMER)
Omeros (NASDAQ:OMER) has insider ownership of 13.60% and institutional ownership of 47.94%.

  • On 12/7/2016 Gregory A Md Demopulos, CEO, sold 306,124 with an average share price of $10.66 per share and the total transaction amounting to $3,263,281.84. View SEC Filing
  • On 12/6/2016 Gregory A Md Demopulos, CEO, sold 102,040 with an average share price of $10.80 per share and the total transaction amounting to $1,102,032.00. View SEC Filing
  • On 12/5/2016 Gregory A Md Demopulos, CEO, sold 102,040 with an average share price of $10.71 per share and the total transaction amounting to $1,092,848.40. View SEC Filing
  • On 12/2/2016 Gregory A Md Demopulos, CEO, sold 306,120 with an average share price of $11.58 per share and the total transaction amounting to $3,544,869.60. View SEC Filing
  • On 9/15/2016 Marcia S Kelbon, VP, sold 16,000 with an average share price of $10.91 per share and the total transaction amounting to $174,560.00. View SEC Filing
  • On 8/15/2016 Marcia S Kelbon, VP, sold 15,900 with an average share price of $11.56 per share and the total transaction amounting to $183,804.00. View SEC Filing
  • On 7/15/2016 Marcia S Kelbon, VP, sold 15,900 with an average share price of $11.50 per share and the total transaction amounting to $182,850.00. View SEC Filing

About Omeros (NASDAQ:OMER)
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement. Its clinical programs include Mannan-binding lectin-associated serine protease-2 (MASP-2) (OMS721)-Lectin Pathway Disorders; PDE10 (OMS824)-CNS Disorders; peroxisome proliferator-activated receptor gamma (PPARy) (OMS405)-Addiction, and OMS201-Urology. Its preclinical programs include phosphodiesterase 7 (PDE7) (OMS527), Plasmin (OMS616), MASP-3 (OMS906)-Alternative Pathway Disorders, GPR17-CNS Disorders, GPR101-Metabolic Disorders, GPR151-CNS Disorders, GPR161-Cancer, GPR174-Immune Disorders, GPR183-Skeletal and Infectious Diseases, GPCR Platform and Antibody Platform.

Recent Trading Activity for Omeros (NASDAQ:OMER)
Shares of Omeros closed the previous trading session at 10.54 down -1.06 -9.14% with 1,432,509 shares trading hands.

An ad to help with our costs